Icodextrin Suppliers & Bulk Manufacturers
Available Forms: sterile Solution bags
Available Strengths: 7.5% w/v
Reference Brands: Extraneal (USA)
Category:
Critical Care
Icodextrin is available in sterile Solution bags
and strengths such as 7.5% w/v.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Icodextrin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Icodextrin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Icodextrin is a high-molecular-weight glucose polymer used as a colloid osmotic agent in peritoneal dialysis and certain gynecological procedures. Marketed under the trade name Extraneal for peritoneal dialysis and Adept for the reduction of post-surgical adhesions, icodextrin is formulated as an aqueous solution designed to provide sustained ultrafiltration and fluid removal. In peritoneal dialysis, the 7.5% icodextrin solution is administered during the once-daily long-dwell exchange, serving as an effective alternative to dextrose-based solutions. Its high molecular weight induces ultrafiltration through a colloid osmotic mechanism rather than hyperosmolar crystalline osmosis, allowing prolonged fluid removal with a lower carbohydrate load.
Compared with dextrose solutions, icodextrin is absorbed more slowly from the peritoneal cavity, providing ultrafiltration of longer duration and reducing systemic glucose exposure. This property is particularly beneficial for patients requiring long-dwell exchanges, improving fluid balance while minimizing metabolic side effects. Clinical studies of up to two years have demonstrated the efficacy and safety of icodextrin in chronic peritoneal dialysis, highlighting its role in optimizing patient care. Additionally, its use in gynecological laparoscopic surgery helps prevent the formation of fibrous adhesions between tissues and organs, further demonstrating its versatility as a medical solution.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing